about
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancersPI3Kγ is a molecular switch that controls immune suppressionRationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapyMulti-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer.Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary GlandsPhase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancerA randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scoresPlanned post-chemoradiation neck dissection: significance of radiation doseDisseminated follicular eruption during therapy with the MEK inhibitor AZD6244Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer
P50
Q30434796-6ADBE354-8643-4ADE-9DB8-D77A502147DCQ33822173-F967834C-72E0-4C25-9002-D8CD76A52CD4Q33839177-3CF72B27-C8FA-43BD-98FE-6E0AE2D9F5AFQ34098286-591977AB-DAF1-4CD0-89BD-3BAED20797C7Q35743883-76DA63D4-4246-4A87-8BD1-C415F8A056F3Q35911903-6B9F3E02-9C7E-4B18-8631-7AD47AE7F97FQ38432573-C3249539-084F-4349-A98B-0D6251F9FC6CQ38583290-0CBF1EE7-5E62-4066-B751-B313AC3AE156Q39931776-24E18FC0-D2A6-4355-8A65-7CBD136AA587Q40266943-73785BA2-C1ED-45C7-AD59-65A58CAB5D41Q42775070-FB6BC6FB-FD56-40D6-A758-E912ADEA7934Q45170619-2332B8B2-3492-4143-8D0F-5B35B89B77A7Q46015106-F0D27C5C-7B0A-41DE-B446-71E31982B8F3Q46308299-A439A71D-F1F2-464F-813F-692B2E47F511Q46813416-242C4EAF-443A-4801-A370-118EE000E92DQ46991010-E3783462-7563-4EE0-9537-DD1FD4E985DCQ57272626-4362939F-CC6D-42BC-8592-C4B65BA4064BQ79757577-F23283FD-532C-4B1A-8D51-F7BBD71571A2Q81408649-8DD77891-ADCC-46F1-8DC5-63794DE37A8EQ82567321-D25277C6-4F22-4C4F-9CBC-70337AC34200Q83215218-A4D52FEA-0B0E-412A-AEBE-DB93615EF14FQ96584096-6FB0807B-0DC2-459E-AA98-09B70D53C12C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ezra E Cohen
@ast
Ezra E Cohen
@en
Ezra E Cohen
@es
Ezra E Cohen
@nl
Ezra E Cohen
@sl
type
label
Ezra E Cohen
@ast
Ezra E Cohen
@en
Ezra E Cohen
@es
Ezra E Cohen
@nl
Ezra E Cohen
@sl
prefLabel
Ezra E Cohen
@ast
Ezra E Cohen
@en
Ezra E Cohen
@es
Ezra E Cohen
@nl
Ezra E Cohen
@sl
P106
P21
P31
P496
0000-0002-9872-6242
P569
2000-01-01T00:00:00Z